ACET Aceto Corporation

Kessler Topaz Meltzer & Check, LLP Announces Investor Class Action Lawsuit Filed Against Aceto Corporation

The law firm of Kessler Topaz Meltzer & Check, LLP announces that an investor class action lawsuit has been filed against Aceto Corporation (Nasdaq: ACET) (“Aceto”) on behalf of purchasers of Aceto common stock between August 25, 2017 and April 18, 2018, inclusive (the “Class Period”).

Aceto investors who purchased securities during the Class Period may, no later than June 25, 2018, seek to be appointed as a lead plaintiff representative of the class.

Investors who wish to discuss this action or request additional information about the lawsuit are encouraged to contact Kessler Topaz Meltzer & Check attorneys James Maro, Jr. or Adrienne Bell at (888) 299-7706 or online at: https://www.ktmc.com/new-cases/aceto-corporation#join

According to the complaint, Aceto is an international company engaged in the development, marketing, sales and distribution of finished dosage form generic pharmaceuticals, nutraceutical products, pharmaceutical active ingredients and intermediates, specialty performance chemicals inclusive of agricultural intermediates and agricultural protection products.

The Class Period commences on August 25, 2017, when Aceto filed a Form 10-K with the SEC announcing the company’s financial and operating results for the fiscal fourth quarter and fiscal year ended June 30, 2017 (“2017 10-K”), which concluded that Aceto’s “internal control over financial reporting as of June 30, 2017, was effective.”

Subsequently, Aceto filed a Form 8-K with the SEC disclosing the non-reliance on its previously issued financial statements and a material weakness in internal control over financial reporting (“November 2017 8-K”).

Then, on April 18, 2018, Aceto issued a press release disclosing non-reliance on the previously issued 2018 fiscal year earnings guidance as well as the recording of non-cash intangible asset impairment charges, including goodwill, in the range of $230-$260 million. Following this news, Aceto’s common stock declined $4.74 from a close price of $7.40 on April 18, 2018, to a close price of $2.66 on April 19, 2018.

The complaint alleges that, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (i) Aceto failed to implement and enforce proper internal control to identify the misapplication of cash; (ii) Aceto would incur large non-cash intangible asset impairment charges; (iii) Aceto lacked effective internal control over financial reporting; (iv) Aceto's financial results for the fiscal year 2017 could not be relied upon; (v) Aceto's fiscal 2018 financial guidance was overstated; and (vi) as a result of the foregoing, Aceto's public statements were materially false and misleading at all relevant times.

Aceto investors may, no later than June 25, 2018, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. In order to be appointed as a lead plaintiff, the Court must determine that the class member’s claim is typical of the claims of other class members, and that the class member will adequately represent the class in the action. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.

Kessler Topaz Meltzer & Check prosecutes class actions in state and federal courts throughout the country. Kessler Topaz Meltzer & Check is a driving force behind corporate governance reform, and has recovered billions of dollars on behalf of institutional and individual investors from the United States and around the world. The firm represents investors, consumers and whistleblowers (private citizens who report fraudulent practices against the government and share in the recovery of government dollars). The complaint in this action was not filed by Kessler Topaz Meltzer & Check. For more information about Kessler Topaz Meltzer & Check, please visit www.ktmc.com.

EN
07/05/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Aceto Corporation

MarketLine Department
  • MarketLine Department

Disproquima SA - Company Profile and SWOT Analysis

Summary Disproquima SA - Company Profile and SWOT Analysis, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Disproquima SA (Disproquima) is a marketer and distributor of wide range of functional ingredients. The company's product portfolio includes active pharmaceutical ingredients, vitamins and minerals, anti...

Adicet Bio Inc: 2 directors

A director at Adicet Bio Inc bought 5,000 shares at 2.400USD and the significance rating of the trade was 62/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...

 PRESS RELEASE

ACETO Completes the Sale of Its Chemicals Business Assets

ACETO Completes the Sale of Its Chemicals Business Assets PORT WASHINGTON, N.Y., April 30, 2019 (GLOBE NEWSWIRE) -- ACETO Corporation (OTC: ACETQ) announced today that it has completed the previously disclosed sale of its chemicals business assets to an affiliate of New Mountain Capital, a leading growth-oriented investment firm with over $20 billion in assets under management. The purchase price paid in the transaction consisted of cash plus the payment of cure costs and the assumption of certain liabilities.  ACETO used a portion of the proceeds from the transaction to repay 100% of ...

 PRESS RELEASE

ACETO to Sell its Chemicals Business Assets to New Mountain Capital

ACETO to Sell its Chemicals Business Assets to New Mountain Capital PORT WASHINGTON, N.Y., April 15, 2019 (GLOBE NEWSWIRE) -- ACETO Corporation (OTC: ACETQ), an international company engaged in the development, marketing, sale and distribution of Human Health products, Pharmaceutical Ingredients and Performance Chemicals, announced today that it has agreed to sell its chemicals business assets to an affiliate of New Mountain Capital (“NMC”), a leading growth-oriented investment firm with over $20 billion in assets under management. The asset purchase agreement was entered into following ...

 PRESS RELEASE

ACETO Receives Court Approval of “Stalking Horse” Agreement to Sel...

ACETO Receives Court Approval of “Stalking Horse” Agreement to Sell Rising Pharmaceuticals to Shore Suven Pharma, Inc. PORT WASHINGTON, N.Y., April 12, 2019 (GLOBE NEWSWIRE) -- ACETO Corporation (OTC: ACETQ), an international company engaged in the development, marketing, sale and distribution of Human Health products, Pharmaceutical Ingredients and Performance Chemicals, announced today that it has received approval from the U.S. Bankruptcy Court  to sell the assets of Rising Pharmaceuticals and Rising’s subsidiaries to Shore Suven Pharma, Inc. for gross cash proceeds of $15 million, plu...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch